Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Ticker
$GLUE
Sector
Primary listing
Employees
187
Headquarters
Website
GLUE Metrics
BasicAdvanced
$1.7bn
-
-$1.50
1.62
-
Price and volume
Market cap
$1.7bn
Beta
1.62
52-week high
$25.77
52-week low
$4.12
Average daily volume
1m
Financial strength
Current ratio
9.538
Quick ratio
9.444
Long term debt to equity
6.626
Total debt to equity
7.485
Profitability
EBITDA (TTM)
-139.941
Gross margin (TTM)
-238.54%
Net profit margin (TTM)
-302.69%
Operating margin (TTM)
-345.21%
Effective tax rate (TTM)
1.42%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-16.41%
Return on equity (TTM)
-32.62%
Valuation
Price to revenue (TTM)
42.191
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-92.197
Free cash flow yield (TTM)
-1.08%
Free cash flow per share (TTM)
-0.225
Growth
Revenue change (TTM)
-73.07%
Earnings per share change (TTM)
-2,024.08%
3-year earnings per share growth (CAGR)
-15.07%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs